Mark MCKelvie

As 2025 draws to a close, U.S. equity markets are once again grappling with a familiar tension. Investors are trying to price in the possibility of future interest rate cuts while simultaneously navigating sharp sector rotations, crowded positioning, and growing dispersion beneath headline index performance. While major benchmarks have held up, leadership has shifted repeatedly,… Continue reading Heading Into Year-End, Aether Holdings (ATHR) Poised to Redefine Investor Intelligence

The biggest constraint on artificial intelligence expansion today is no longer the supply of semiconductors. It is power. AI data centers demand enormous, uninterrupted electricity at scales most grids were never designed to handle. As workloads accelerate worldwide, governments, sovereign investors, and infrastructure operators are confronting a hard truth: without reliable, scalable baseload energy, AI… Continue reading AI’s Power Bottleneck Is Shaping Two Public-Market Setups: Trump Media & Technology Group (NASDAQ: DJT) and VivoPower International PLC (NASDAQ: VVPR)

Actinium Pharmaceuticals (NYSE American: ATNM) is advancing its Trop-2–targeted ATNM-400 construct into Phase 1/2 trials across the United States and Australia, marking an important step as the company broadens its presence in solid-tumor radiopharmaceuticals. With targeted alpha radiotherapy gaining momentum worldwide, the program reinforces Actinium’s position as one of the more established players developing actinium-225–based… Continue reading Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase 1/2 Trials in the U.S. and Australia         

Innovation in oncology continues to accelerate, with global cancer R&D spending now exceeding hundreds of billions annually and more than a thousand new trials launched each year. Among the fastest-growing segments is radiopharmaceuticals, attracting significant investment as major pharmaceutical companies expand into precision radiation therapies. Growth has been fueled by strong clinical performance, improving isotope… Continue reading Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) Begins European Phase 1 Trial of Nectin-4 Targeted Alpha Therapy for Multiple Solid Tumors

Retail trading has emerged as a powerful force in global markets, with participation rising from roughly 25% of all trading activity in 2020 to over 30% by 2024. This surge has driven growing demand for social investing tools, copy trading features, and automated strategies, with analysts projecting these platforms could generate several billion dollars in… Continue reading FDCTech, Inc. (OTC: FDCT) Poised to Capitalize on the Retail Trading Boom

Targeted radiotherapy has become one of the hottest areas in oncology, driving more than $30 billion in pharma deals over the past three years. Prostate, lung, and breast cancer alone account for over $60 billion in annual drug spending, yet resistance to current therapies continues to create costly failures. Actinium Pharmaceuticals (NYSE American: ATNM) is… Continue reading Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances ATNM-400 Targeting STEAP-1 Across Prostate, Breast, and Lung Cancer

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is expanding its radiotherapeutic platform beyond hematologic cancers with ATNM-400, a next-generation candidate designed to deliver targeted radiation against B7-H3, an immune-checkpoint molecule highly expressed across multiple solid tumors. B7-H3 overexpression is linked to tumor aggressiveness, immune evasion, and treatment resistance, making it an increasingly important target. By pairing… Continue reading ATNM-400 Targets B7-H3 and Is Being Studied in a Phase 1 Clinical Trial in South Africa           

Skin cancer is the most common cancer in the U.S., with more than five million non-melanoma cases, overwhelmingly basal cell carcinomas, diagnosed annually. Aging populations, increased sun exposure, and rising detection rates are driving demand for treatment. Against this backdrop, Medicus Pharma (NASDAQ: MDCX) emerges as a compelling small-cap opportunity. The company is developing SkinJect(TM),… Continue reading Disrupting a $6 Billion Skin Cancer Market: The Small-Cap Biotech (MDCX) Advancing a Non-Surgical Patch  

Artificial intelligence is transforming how investors interpret markets, but one area is quickly emerging as the new frontier: real-time sentiment analytics linked directly to investor-focused media. With the AI-driven financial analytics market projected to reach $28 billion by 2029, demand is shifting toward platforms that can combine behavioral signals, predictive modeling, and continuous data inputs… Continue reading Aether Holdings, Inc. (NASDAQ: ATHR) Targets $28B AI Analytics Market With a Data-Media Ecosystem Strategy